# COSMIC-313 (NCT03937219)

> Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03937219
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Exelixis
- Conditions: Renal Cell Carcinoma
- Interventions: Cabozantinib; Nivolumab; Ipilimumab; Cabozantinib-matched placebo
- Enrollment: 855
- Primary outcome: Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)

## Commentary we found

- X threads: 104
- Podcasts: 65
- YouTube: 52
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cosmic-313-nct03937219

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03937219", "email": "<work email>"}; the inbox owner confirms by the emailed link.